Azora Therapeutics, Inc. is left out of our screens and market counts tonight, which cover US stocks priced at $5 or more and trading at least $1 million a day on average. Its read below still updates after every close.
Azora Therapeutics, Inc.
As of Nov 3, 2026, Azora Therapeutics is in Stage 3, the topping phase, now in its first week (since Oct 30, 2026). It closed at $4.15, 52.6% below its 52-week high and above its 200-day average, which is falling. In Health Care, 37.4% of stocks are in Stage 2.
Every stock that changed stage on Oct 30, 2026 →
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. More about the company
Pro read
ProOur read
Setup score
Momentum
Is AZR early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
AZR among Biotechnology
All 237 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | IOVA | Stage 2 · wk 20 | 99 | −37.6% |
| 2 | SLS | Stage 3 · wk 6 | 99 | −23.7% |
| 3 | MRNA | Stage 2 · wk 19 | 99 | +12.4% |
| 4 | SYRE | Stage 3 · wk 6 | 99 | +7.1% |
| 5 | TWST | Stage 2 · wk 41 | 99 | −31.6% |
| 6 | KOD | Stage 2 · wk 5 | 99 | +5.4% |
| 7 | ERAS | Stage 3 · wk 6 | 99 | −0.5% |
| 8 | CLYM | Stage 3 · wk 5 | 99 | −11.8% |
Against its industry
Biotechnology · 592 companies we cover
- Return on equity-2011.6%
Higher return on equity than 1%
- Profit margin0.0%
Wider margin than 18%
- Dividend yield0.00%
Higher yield than 0%
Azora Therapeutics: quick answers
What stage is Azora Therapeutics in?
As of Nov 3, 2026, Azora Therapeutics (AZR) is in Stage 3, the topping phase. It entered Stage 3 on Oct 30, 2026 and is in its first week there. What the four stages mean
Is Azora Therapeutics in an uptrend?
Its uptrend has stalled. Azora Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 29.4% above its 200-day average, which is falling.
How far is Azora Therapeutics from its 52-week high?
Azora Therapeutics closed at $4.15 on Nov 3, 2026, 52.6% below its 52-week high of $8.75. Its 52-week low is $1.36.
How has Azora Therapeutics performed over the past year?
As of Nov 3, 2026, Azora Therapeutics is down 52.6% over the past year and down 30.8% so far in 2026.
Which sector and industry is Azora Therapeutics in?
Azora Therapeutics is in the Biotechnology industry, part of the Health Care sector. 187 stocks in Health Care are in Stage 2, 37.4% of the sector. See the Stage 2 stocks in Biotechnology
About this companyHealth Care· Biotechnology
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Visit company website →All analytics based on EOD data. Data as of 2026-11-03. Past data patterns are not indicative of future results. This page is a data analytics tool only.